A randomised factorial trial of sequential doxorubicin and CMF vs CMF and chemotherapy alone vs chemotherapy followed by goserelin plus tamoxifen as adjuvant treatment of node-positive breast cancer.

Br J Cancer · 2005 · PMC2362097 · PMID 15668708

Europe PMC DOI

hedged sentences

0.4800

closest p · 9.6× alpha

0.4800

boldest claim

The sentences

did not reach statistical significanceP =0.48not close (p > 0.1)

The difference did not reach statistical significance at univariate log-rank test ( P =0.48) or at Cox's multivariate analysis (HR=0.84; 95% CI: 0.54–1.32).

also in 111,027 other papers

just failed to reach statistical significanceno p-value reported

At a median follow-up of 6.2 years, there was a trend in favour of improved DFS for the addition of goserelin to CAF, although this just failed to reach statistical significance.

also in 203 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.